Vimseltinib elicited an ORR of 40% vs 0% of matching placebo in patients with tenosynovial giant cell tumor in the phase 3 MOTION trial.
Approval Alert | Vimseltinib in Tenosynovial Giant Cell Tumors
Advertisement
Advertisement
Trending on CancerNetwork
1
BCMA CAR T-Cell Therapy Improves OS Vs Teclistamab in Multiple Myeloma
2
FDA Grants Priority Review to Giredestrant in ER+/HER2– Early Breast Cancer
3
GLP-1 Receptor Agonists Show Modest Reduction in HR+ Breast Cancer Incidence
4
Decoding RAMPART: Durvalumab Monotherapy Vs Combination Therapy in RCC
5